Therachon, a Basel, Switzerland-based biotechnology company focused on rare genetic diseases, raised $5m in the final close of its Series A financing.
The Series A now stands at $40m and includes founding investors Versant Ventures and Inserm Transfer Initiative (ITI), existing investor OrbiMed and new investor Banque publique d’investissement (Bpifrance).
The company intends to use the funds to advance its emerging portfolio, including its lead program in achondroplasia, the most common form of short-limbed dwarfism. In conjunction with the financing, Bpifrance’s Chahra Louafi has joined the company’s Board of Directors.
Led by newly appointed Chief Executive Officer and Director Luca Santarelli, M.D., Therachon is a global biotechnology company focused on developing treatments for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism.
Dr. Santarelli brings over 20 years of experience in academic, industrial research and development, and business experience from his role as Venture Partner at Versant Ventures. In addition to his training as both a discovery scientist and clinician, he has deep operating experience from his progressive leadership responsibilities at Roche, most recently serving as Senior Vice President and Global Head of Neuroscience, Ophthalmology and Rare Diseases.